Accepting subscription rights to new shares
Commissioning the development of regenerative medical products to promote market introduction
FUJIFILM Corporation (President: Shigehiro Nakajima; Hereinafter “Fujifilm”) has decided to accept all of the 18,000 subscription rights (to 18,000 shares)** to be issued by Japan Tissue Engineering Co., Ltd. (President: Yosuke Ozawa; Hereinafter “J-TEC”), a company that deals with regenerative medicine products*.
J-TEC is to be commissioned to develop regenerative medicine products that utilize a type of collagen with excellent biocompatibility (recombinant peptide: RCP***), developed by Fujifilm, for future market introduction. Through this operation, Fujifilm is further reinforcing its partnership with J-TEC to accelerate its initiative for the practical application of regenerative medicine.
Tapping into technologies and know-how accumulated in the R&D and manufacturing of photographic films, Fujifilm has been developing RCP, which can be processed into various formulation as the “scaffold”*4 to aid cell growth and proliferation, required in regenerative medicine. The company has boosted its regenerative medicine business and its R&D structure, as seen in the establishment of the Regenerative Medicine Business Development Office and the Regenerative Medicine Research Laboratories in September last year. Fujifilm has high function materials produced with process control technology that forms the foundation of RCP, engineering technology for precision structuring, as well as diagnostic imaging and analysis technologies that can be applied to regenerative medicine and effective in bio-imaging. The company plans to combine them with J-TEC's multi-faceted technological capacity and know-how in areas covering research, development, production and marketing to promote the development and commercialization of regenerative medicine products.
The promotion of regenerative medicine's practical application is one of key items in Abenomics growth strategies. In November last year, the Diet passed the bill on the Act on Ensuring Regenerative Medicine Safety and the bill for partially amending the Pharmaceutical Affairs Act for effectuation by the end of this year. Among the provisions of these laws, the fast-track approval scheme that supports early commercialization of regenerative medicine products, and the outsourcing of cell processing from medical institutions to external companies, are described as a form of deregulation that accelerates the industrialization of regenerative medicine in Japan. In the given situation, Fujifilm is committed to further strengthening partnership with J-TEC to promote the establishment of the regenerative medicine industry.
J-TEC is Japan's only bio-venture enterprise that deals with regenerative medical products. It has obtained approval for manufacturing and distribution of Autologous Cultured Epidermis*5, “JACE”, and Autologous Cultured Cartilage*6, “JACC”.